Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors

BACKGROUND: Ovarian cancer is the most fatal gynecologic malignancy in the United States. While chemotherapy is effective in the vast majority of ovarian cancer patients, recurrence and resistance to standard systemic therapy is nearly inevitable. We discovered that activation of the non-receptor ty...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Ovarian Res
Autors principals: Crean-Tate, Katie K., Braley, Chad, Dey, Goutam, Esakov, Emily, Saygin, Caner, Trestan, Alexandria, Silver, Daniel J., Turaga, Soumya M., Connor, Elizabeth V., DeBernardo, Robert, Michener, Chad M., Rose, Peter G., Lathia, Justin, Reizes, Ofer
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8063392/
https://ncbi.nlm.nih.gov/pubmed/33888137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-021-00797-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars